spacer
home > ebr > spring 2018 > tomorrows treatment
PUBLICATIONS
European Biopharmaceutical Review

Tomorrows Treatment

Ever since the time of Hippocrates who wrote about the individuality of disease and the necessity of giving different drugs to different patients – “for the sweet ones do not benefit everyone, nor do the astringent ones, nor are all the patients able to drink the same things” – a personalised approach to medicine has been recognised steadily, but it is only in recent decades that a fuller scientific understanding of the approach has become better appreciated.

However, the decoding of the human genome in 2003 saw a step-change in the acceleration of that understanding, and the medical community has long predicted that an era of personalised medicine will soon be ubiquitous. This article examines how that reality is now upon us and that the use of biomarkers and personalised medicine in oncology is transforming current cancer treatments.

New Ideas

While established cancer treatments such as surgery, radiation, and chemotherapy are still improving, excitement in the cancer arena today lies in the development of targeted therapies, otherwise known as ‘personalised medicine’. This individualised approach includes not only the early stage diagnosis of every specific cancer, tailor-made therapeutic intervention, and the careful monitoring of patients’ progress, but also heralds the prospect of personalised treatments that stimulate the body’s immune system to fight cancer.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tarquin Edwards is a writer, freelance journalist, and advisor to a number of publicly-quoted and private companies in the biotechnology and biopharmaceutical sectors. He is Managing Director of Peckwater PR, a media and IR consultancy, which he founded in 2009. Tarquin has over 20 years’ experience working in the financial PR industry, coordinating and implementing media and IR campaigns on behalf of mid- to smaller-quoted and privately owned companies. He has a Masters degree from Oxford University, UK and a BA (Hons) degree from the University of London (Royal Holloway), UK.
spacer
Tarquin Edwards
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am ET on June 20.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

SMi presents the 13th Conference on ADMET

9-10 July 2018, Holiday Inn Kensington Forum, London, UK

SMi is delighted to announce the 13th annual ADMET conference returning to London to explore the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement